Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
2.310
0.00 (0.00%)
Jul 13, 2026, 9:48 AM EDT - Market open
Jaguar Health Employees
Jaguar Health had 47 employees as of December 31, 2025. The number of employees decreased by 2 or -4.08% compared to the previous year.
Employees
47
Change (1Y)
-2
Growth (1Y)
-4.08%
Revenue / Employee
$629,128
Profits / Employee
-$1,066,511
Market Cap
1.39M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 47 | -2 | -4.08% |
| Dec 31, 2024 | 49 | 0 | - |
| Dec 31, 2023 | 49 | -11 | -18.33% |
| Dec 31, 2022 | 60 | 8 | 15.38% |
| Dec 31, 2021 | 52 | 18 | 52.94% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Scinai Immunotherapeutics | 45 |
| Calidi Biotherapeutics | 29 |
| Silexion Therapeutics | 14 |
| VivoSim Labs | 14 |
| Azitra | 13 |
| Biodexa Pharmaceuticals | 11 |
| CDT Equity | 4 |
JAGX News
- 13 days ago - Jaguar Health provides recap of presentations of crofelemer at ESPGHAN - TheFly
- 13 days ago - Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) - Accesswire
- 18 days ago - Jaguar Health announces conversion of Series O convertible preferred stock - TheFly
- 18 days ago - Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend - Accesswire
- 18 days ago - Jaguar Health Transcript: Life Sciences Virtual Investor Forum - Transcripts
- 19 days ago - Jaguar Health completes submission of NADA to U.S. FDA for crofelemer - TheFly
- 20 days ago - Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire
- 21 days ago - Jaguar Health initiates process to explore, review strategic alternatives - TheFly